Dec 2, 2024 • 7:30 AM EST XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Nov 7, 2024 • 7:30 AM EST XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
